Seastar Medical Holding Corp. - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Seastar Medical Holding Corp. (ICU) is a commercial-stage healthcare company developing the Selective Cytopheretic Device (SCD) to treat hyperinflammation. The company commercializes QUELIMMUNE, an FDA-approved pediatric SCD therapy for acute kidney injury (AKI) due to sepsis, and is conducting a pivotal clinical trial (NEUTRALIZE-AKI) for adult patients. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenue | $495 | $293 |
| Gross Profit | $449 | $293 |
| Net Loss | $(3,521) | $(3,772) |
| Net Loss Per Share (Basic/Diluted) | $(0.90) | $(4.38) |
| Cash and Cash Equivalents (End of Period) | $9,348 | $5,296 |
| Accumulated Deficit | $(155,235) | $(143,336) |
| Notes Payable (Current) | $331 | $525 |
| Net Cash Used in Operating Activities | $(2,761) | $(2,654) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased by 69% ($202k) to $495k, driven by increased customer adoption of QUELIMMUNE.
- Cost of Goods Sold (COGS): COGS appeared for the first time in Q1 2026 at $46k, as inventory was previously expensed as R&D prior to commercial sales.
- Operating Expenses: Total operating expenses decreased slightly by 2% ($63k) to $4.05 million. R&D expenses declined 4% due to reduced clinical trial site costs, partially offset by increases in payroll and external services. G&A expenses increased 1% due to legal and marketing costs, offset by reduced compensation costs.
- Liquidity: Cash balances decreased by $2.6 million during the quarter due to operating cash burn, despite a $0.3 million net inflow from financing activities (equity issuance).
- Stock Structure: The company effected a 1-for-10 reverse stock split on January 5, 2026, in addition to a prior 1-for-25 split in 2024.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management states that cash on hand ($9.3 million) is insufficient to fund operations for the next 12 months. The filing explicitly raises substantial doubt about the company's ability to continue as a going concern.
- Capital Needs: The company expects to finance operations through equity sales (SEPA with Lincoln Park Capital, ATM program), debt, or strategic collaborations. The ATM program is currently restricted due to "baby shelf" limitations.
- Clinical Progress: The company enrolled the 50th patient in the SAVE Surveillance Registry for QUELIMMUNE in March 2026, meeting the reduced FDA requirement. The pivotal NEUTRALIZE-AKI trial for adults is ongoing, with topline results and potential PMA submission anticipated in 2027.
- Legal Proceedings: A putative class action lawsuit regarding financial restatements was dismissed with prejudice in April 2026. A derivative action remains stayed pending further developments.
- Nasdaq Compliance: The company regained compliance with the minimum bid price requirement in January 2026 but remains under a Mandatory Panel Monitor until July 1, 2026, regarding stockholders' equity requirements.
Investor Verification Checklist
- Verify the sufficiency of the $9.3 million cash balance against the projected burn rate and the timeline for the next capital raise.
- Confirm the status of the Standby Equity Purchase Agreement (SEPA) with Lincoln Park Capital and the remaining $14.7 million capacity.
- Monitor the progress of the NEUTRALIZE-AKI pivotal trial and the timeline for the 2027 PMA submission.
- Review the terms of the insurance financing note payable ($331k) and any potential covenants.
- Assess the impact of the reverse stock splits on warrant exercise prices and potential dilution from future equity offerings.